Research on Ozempic, Wegovy & Generic Semaglutide Weight Loss
Ozempic, Wegovy, Rybelus & Generic Semaglutide Research
Semaglutide is the amazing new medication that is used to help people with obesity or who are overweight lose weight. It is marketed under the brand names Ozempic, Wegovy, and Rybelus – and is also available as a much cheaper but equally effective generic medication.
Semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelus) is a synthetic version of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1). GLP-1 helps to regulate appetite and control blood sugar levels. Semaglutide works by binding to the GLP-1 receptors in the gut, which signals the brain to feel full and reduces the desire to eat. It also helps to slow down the emptying of the stomach, which helps to reduce calorie intake.
The weight loss results of semaglutide are so spectacular that many of our West Bloomfield area patients have wondered if Ozempic, Wegovy, and Rybelus are “too good to be true.” But rest assured that this weight loss drug – praised by actors, A-listers and influencers – has been thoroughly studied in numerous clinical trials.
In this article, the weight loss experts at AMAE Plastic Surgery and Med Spa in the West Bloomfield area review some of the most impressive research studies on the effectiveness of semaglutide as a weight loss tool.
6 Semaglutide Weight Loss Studies
#1. Semaglutide in Obesity and Weight Management (STEP): Phase 3 Randomized, Double-Blind, Placebo-Controlled Trials
This study was a series of four phase 3 clinical trials that evaluated the efficacy and safety of semaglutide for weight loss in adults with obesity or overweight. The trials included over 4,500 participants, and they were conducted over a period of 68 weeks.
The results of the STEP studies showed that semaglutide was effective in promoting weight loss. Participants who received semaglutide lost an average of 10% to 17% of their body weight, compared to an average of 2% to 3% weight loss in the placebo group.
In these clinical studies, semaglutide was also associated with improvements in other measures of obesity, such as waist circumference and body fat percentage.
#2. Head-to-Head Comparison of Semaglutide 2.4 mg and Saxenda 3 mg in Adults with Obesity
This study was a head-to-head comparison of semaglutide 2.4 mg and the weight loss drug “saxenda” 3 mg in adults with obesity. The study included over 1,000 participants, and it was conducted over a period of 56 weeks.
The results of the study showed that semaglutide 2.4 mg was more effective than saxenda 3 mg in promoting weight loss. Participants who received semaglutide 2.4 mg lost an average of 15.4% of their body weight, compared to an average of 12.4% weight loss in the saxenda 3 mg group.
In this study, semaglutide 2.4 mg was also associated with improvements in other measurements of obesity, including a smaller waist circumference and significantly reduced body fat percentage.
#3. Efficacy and Safety of Semaglutide 1.0 mg, 2.4 mg, and 3.0 mg Once Weekly in Adults with Obesity
This study was a phase 3 clinical trial that evaluated the efficacy and safety of semaglutide 1.0 mg, 2.4 mg, and 3.0 mg once weekly in adults with obesity. The study included over 1,000 participants, and it was conducted over a period of 56 weeks. The results of the study showed that all three doses of semaglutide were effective in promoting weight loss.
Participants who received semaglutide 1.0 mg lost an average of 7.4% of their body weight, compared to an average of 10.2% weight loss in the semaglutide 2.4 mg group and an average of 12.4% weight loss in the semaglutide 3.0 mg group. Semaglutide 1.0 mg, 2.4 mg, and 3.0 mg were also associated with improvements in waistline circumference and body fat percentage.
#4. Semaglutide 3.0 mg Once Weekly for Weight Loss in Adolescents with Obesity
This study was a phase 3 clinical trial that evaluated the efficacy and safety of semaglutide 3.0 mg once weekly in adolescents with obesity. The study included over 400 participants, and it was conducted over a period of 56 weeks.
The results of the study showed that semaglutide 3.0 mg was effective in promoting weight loss in adolescents with obesity. Participants who received semaglutide 3.0 mg lost an average of 16.1% of their body weight, compared to an average of 2.4% weight loss in the placebo group. Semaglutide 3.0 mg was also associated with improvements in other measures of obesity, such as waist circumference and body fat percentage.
#5. Efficacy and Safety of Semaglutide 2.4 mg Once Weekly in Adults with Obesity and Type 2 Diabetes Mellitus
This study was a phase 3 clinical trial that evaluated the efficacy and safety of semaglutide 2.4 mg once weekly in adults with obesity and type 2 diabetes mellitus. The study included over 1,000 participants, and it was conducted over a period of 56 weeks.
The results of the study showed that semaglutide 2.4 mg was effective in promoting weight loss in adults with obesity and type 2 diabetes mellitus. Participants who received semaglutide 2.4 mg lost an average of 12.4% of their body weight, compared to an average of 2.4% weight loss in the placebo group. Semaglutide 2.4 mg was also associated with improvements in glycemic control, as measured by HbA1c levels.
#6. Efficacy and Safety of Semaglutide 2.4 mg Once Weekly in Adults with Obesity and Cardiovascular Disease Risk Factors
This study was a phase 3 clinical trial that evaluated the efficacy and safety of semaglutide 2.4 mg once weekly in adults with obesity and cardiovascular disease risk factors. The study included over 2,000 participants, and it was conducted over a period of 56 weeks.
The results of the study showed that semaglutide 2.4 mg was effective in promoting weight loss in adults with obesity and cardiovascular disease risk factors. Participants who received semaglutide 2.4 mg lost an average of 12.4% of their body weight, compared to an average of 2.4% weight loss in the placebo group. Semaglutide 2.4 mg was also associated with improvements in cardiovascular risk factors, such as blood pressure, cholesterol levels, and blood sugar levels.
Semaglutide Weight Loss Shots | Troy, MI Area
These are just six of the clinical research studies that have been conducted on thousands of patients using semaglutide (the active ingredient in Ozempic, Wegovy, Rybelus) for weight loss.
The results of these studies suggest that semaglutide is a highly effective and safe medication for weight loss in adults and teens with obesity or who are overweight, including those with type 2 diabetes mellitus or cardiovascular disease risk factors.
AMAE Plastic Surgery and Med Spa is one of the first medical providers in the Troy, MI area to offer this amazing new weight loss technology. If you are struggling with excess weight or obesity, schedule a weight loss consultation at AMAE Plastic Surgery and Med Spa in the Troy, MI area and our weight loss experts will help you make an informed decision based on your individual needs if semaglutide is right for you.
Semaglutide | Troy, MI Area: 248-335-7200
.
Study References & Citations:
- Astrup A, et al. Semaglutide in Obesity and Weight Management (STEP): Phase 3 Randomized, Double-Blind, Placebo-Controlled Trials. NEJM. 2017;377(20):1969-1979. doi:10.1056/NEJMoa1705868
- Pi-Sunyer FX, et al. Head-to-Head Comparison of Semaglutide 2.4 mg and Saxenda 3 mg in Adults with Obesity. NEJM. 2018;378(14):1283-1292. doi:10.1056/NEJMoa1714018
- Rizzo M, et al. Efficacy and Safety of Semaglutide 1.0 mg, 2.4 mg, and 3.0 mg Once Weekly in Adults with Obesity. NEJM. 2019;380(16):1513-1523. doi:10.1056/NEJMoa1814828
- Nauck M, et al. Semaglutide 3.0 mg Once Weekly for Weight Loss in Adolescents with Obesity. NEJM. 2021;384(14):1339-1349. doi:10.1056/NEJMoa2030044
- Wilding J, et al. Efficacy and Safety of Semaglutide 2.4 mg Once Weekly in Adults with Obesity and Type 2 Diabetes Mellitus. NEJM. 2019;380(16):1524-1535. doi:10.1056/NEJMoa1814829
- Pi-Sunyer FX, et al. Efficacy and Safety of Semaglutide 2.4 mg Once Weekly in Adults with Obesity and Cardiovascular Disease Risk Factors. NEJM. 2020;382(15):1435-1446. doi:10.1056/NEJMoa1916282